My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Emmessar Biotech & Nutrition to conduct board meeting
Jul 22,2017

Emmessar Biotech & Nutrition will hold a meeting of the Board of Directors of the Company on 1 August 2017.

Powered by Capital Market - Live News

Advanced Micronic Devices announces board meeting date
Jul 22,2017

Advanced Micronic Devices will hold a meeting of the Board of Directors of the Company on 1 August 2017.

Powered by Capital Market - Live News

Multiplus Holdings to discuss results
Jul 22,2017

Multiplus Holdings will hold a meeting of the Board of Directors of the Company on 12 August 2017.

Powered by Capital Market - Live News

Wires & Fabriks (S.A) to table results
Jul 22,2017

Wires & Fabriks (S.A) will hold a meeting of the Board of Directors of the Company on 31 July 2017.

Powered by Capital Market - Live News

Switching Technologies Gunther to declare Quarterly Result
Jul 22,2017

Switching Technologies Gunther will hold a meeting of the Board of Directors of the Company on 28 July 2017.

Powered by Capital Market - Live News

Mangalore Chemicals & Fertilizers to declare Quarterly Result
Jul 22,2017

Mangalore Chemicals & Fertilizers will hold a meeting of the Board of Directors of the Company on 29 July 2017.

Powered by Capital Market - Live News

Oriental Carbon & Chemicals to hold board meeting
Jul 22,2017

Oriental Carbon & Chemicals will hold a meeting of the Board of Directors of the Company on 28 July 2017.

Powered by Capital Market - Live News

Rishiroop to announce Quarterly Result
Jul 22,2017

Rishiroop will hold a meeting of the Board of Directors of the Company on 5 August 2017, for considering redemption of the outstanding Redeemable Preference Shares (RPS)

Powered by Capital Market - Live News

Danlaw Technologies India to announce Quarterly Result
Jul 22,2017

Danlaw Technologies India will hold a meeting of the Board of Directors of the Company on 12 August 2017, to consider the Un-Audited Financial Results for the quarter ended 30 June 2017

Powered by Capital Market - Live News

Voltamp Transformers schedules AGM
Jul 22,2017

Voltamp Transformers announced that the 50th Annual General Meeting (AGM) of the company will be held on 12 August 2017.

Powered by Capital Market - Live News

Brand Realty Services announces board meeting date
Jul 22,2017

Brand Realty Services will hold a meeting of the Board of Directors of the Company on 31 July 2017, to consider and approve, inter-alia, the Un-Audited Standalone Financial Results of the Company for the Quarter ended 30th June 2017.

Powered by Capital Market - Live News

Ugar Sugar Works to announce Quarterly Result
Jul 22,2017

Ugar Sugar Works will hold a meeting of the Board of Directors of the Company on 11 August 2017, to approve and take on record Un audited Financial Result and Segment wise Revenue Result for the Quarter ended 30th June 2017.

Powered by Capital Market - Live News

Century Textiles & Industries announces board meeting date
Jul 22,2017

Century Textiles & Industries will hold a meeting of the Board of Directors of the Company on 8 August 2017, to consider and take on record the Unaudited Financial Results of the Company for the First Quarter (April to June) ended on 30th June, 2017

Powered by Capital Market - Live News

GDL Leasing & Finance to hold board meeting
Jul 22,2017

GDL Leasing & Finance will hold a meeting of the Board of Directors of the Company on 29 July 2017.

Powered by Capital Market - Live News

Astrazeneca Pharma India to launch Osimertinib Tablets (Tagrisson++)
Jul 22,2017

Astrazeneca Pharma India will launch Osimertinib 40 mg and 80 mg (Tagrisson++) in India on 27 July 2017.

Osimertinib 40 mg and 80 mg (Tagrisson++) is an oral anti-cancer drug for management of lung cancer. It is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an appropriate test, whose disease has progressed on or after EGFR TKI therapy.

Osimertinib (Tagrisson++) is the product of AstraZeneca group and has been approved in over 45 countries, including US, EU, Japan, China and other Asian countries.

Powered by Capital Market - Live News